Genetic Signatures Ltd (ASX: GSS) Share Price and News

Ms Waldron is a cross-border advisor and director with over 30 years expertise in governance, marketing, human resources, and digital transformation across a range of sectors. Her formal training is in law, and she has been admitted to the Bar of England and Wales and the courts of other jurisdictions including Australia and New Zealand. She is a member of the Risk Committee.

Dr Harry has over 25 years experience in executive management of companies in the biotechnology, diagnostic and pharmaceutical sectors. She is a CEO with experience in growing companies from start-up to commercialisation. Dr Harry is currently a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX: NEU) and Aeris Environmental Ltd (ASX: AEI) and is a member of the IP Committee of the Childrens Medical Research Institute.

Mr Samaras has had over 30 years of business experience in the global Life Sciences industry and is a industry expert. He has held several senior executive level positions in management, marketing, sales, and research and development. His roles have included appointments as Managing Director of Applied Biosystems Pty Ltd (now part of Thermo Fisher), and senior roles with Perkin Elmer and AMRAD Corporation now part of CSL. Dr. Samaras is an experienced executive, non-executive and Board Chairman, having served on the boards of several biotechnology companies. He is a member of the Risk Committee.

Mr Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute NGI which was acquired by Laboratory Corporation of America,Inc.LabCorp in 2000.Mr Aicher led LabCorp's Esoteric Business Units, which generated more than $1 billion in annual revenue. Prior to NGI, Mr. Aicher served in several executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of Roswell Biotechnologies,Techcyte and CytoBay.

Mr Gunn has over 30 years of experience in medical devices and diagnostics. Most recently Dr Gunn was CEO of IDbyDNA, a metagenomics company based in the US that was acquired by Illumina in 2022. Prior to this he was the President of Roche Sequencing Solutions where he oversaw all aspects of the business and managed a team of approximately 900 people. His team developed and launched more than 20 products per year. Dr Gunn was also previously Vice President of Roche's Molecular Diagnostics business and was responsible for over 120 diagnostic product launches principally into the IVD clinical market.

Ms Lockwood, is currently a Non-Executive Director for the ASX-listed company Mayne Pharma and Chief Financial Officer for Planet Innovation. She brings finance and accounting as well as US operations experience gained from senior executive roles in healthcare and life science companies.

-

-

-

-